Small Cap Losers: Inovio Pharmaceuticals (NYSEMKT:INO), ZIOPHARM Oncology (NASDAQ:ZIOP), BioCryst Pharmaceuticals (NASDAQ:BCRX), NQ Mobile Inc (NYSE:NQ)

The Inovio Pharmaceuticals Inc (NYSEMKT:INO) on Apr. 1 announced the appointment of E.J. Brandreth as Vice President of Quality. He will be responsible for all quality and compliance functions for a company that is moving forward with numerous late and early stage clinical trials and scaling up manufacturing and other operational areas to support its broad pipeline of immunotherapies and DNA vaccines. He will report to Inovio’s Chief Operating Officer Dr. Niranjan Sardesai. Prior to joining Inovio, Mr. Brandreth had a successful career transitioning start-up clinical biotech operations into successful commercial entities; he supported the growth of several pharmaceutical companies in the quality and compliance areas. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $2.91 moved to $2.98 on last trade day and at the end of the day closed at $2.67. Company price to sales ratio in past twelve months was calculated as 47.49 and price to cash ratio as 12.19. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -9.80%.

Mizuho assumed coverage on shares of ZIOPHARM Oncology (NASDAQ:ZIOP) in a research note issued on Wednesday,TheFlyOnTheWall.com reports. The firm set a “buy” rating on the stock.ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) shares fell -5.90% in last trading session and ended the day on $3.39. ZIOP return on equity ratio is recorded as -207.30% and its return on assets is -108.70%. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) yearly performance is 101.79%.

Shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) have received a consensus rating of “Buy” from the twelve analysts that are presently covering the company, American Banking News reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.57.BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares moved down -7.41% in last trading session and was closed at $8.25, while trading in range of $8.01-$9.37. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) year to date performance is 8.55%.

TheStreet Ratings team rates NQ Mobile Inc (ADR) (NYSE:NQ) as a Hold with a ratings score of C. TheStreet Ratings Team has this to say about their recommendation:We rate NQ MOBILE INC -ADR (NQ) a HOLD. The primary factors that have impacted our rating are mixed – some indicating strength, some showing weaknesses, with little evidence to justify the expectation of either a positive or negative performance for this stock relative to most other stocks. NQ Mobile Inc (ADR) (NYSE:NQ) weekly performance is -30.11%. On last trading day company shares ended up $11.05. NQ Mobile Inc (ADR) (NYSE:NQ) distance from 50-day simple moving average is -39.63%. Analysts mean target price for the company is $30.58.